Healome Therapeutics raises $2.7M seed
Healome Therapeutics raised $2.7M in seed funding, announced on 8 May 2025, led by Empirical Ventures, with participation from DEBRA Research, Cure EB, Oshen Bio, SFC Capital. The round is tracked live by Fusion42 as part of the Raise fund database and the Scout startup database.
University of Birmingham spinout developing a proprietary eye-drop matrix platform for ocular surface diseases. Healome Therapeutics is based in United Kingdom and currently at seed stage, operating in healthtech, deeptech.
Empirical Ventures and SFC Capital are profiled on Raise, Fusion42's database of venture funds — where each investor's thesis, cheque size and other tracked backings can be followed. This funding event is a citable node in Fusion42's market graph: it links Healome Therapeutics's Scout profile to the funds behind the round and to related Wire analysis, and is refreshed from public announcements as the round is confirmed or extended. It is the same live market data Arthur, Fusion42's AI co-founder, reasons over when benchmarking a founder's own raise against what is closing in the market right now.
Round details
| Company | Healome Therapeutics |
| Stage | seed |
| Amount | $2.7M |
| Announced | 8 May 2025 |
| Lead | Empirical Ventures |
| Participation | DEBRA Research, Cure EB, Oshen Bio, SFC Capital |
| Source | announcement ↗ |
Investing funds on Raise
Explore: Seed · United Kingdom
Frequently asked questions
- How much did Healome Therapeutics raise?
- Healome Therapeutics raised $2.7M in its seed round, announced 2025-05-08.
- Who invested in Healome Therapeutics's seed round?
- The round was led by Empirical Ventures, with participation from DEBRA Research, Cure EB, Oshen Bio and SFC Capital.
- What does Healome Therapeutics do?
- University of Birmingham spinout developing a proprietary eye-drop matrix platform for ocular surface diseases.
Verified 17 July 2026 · Sources: public filings